Japan's Ono Pharma dives after Merck's Keytruda leads in lung cancer

ONO PHARMACEUTICAL

17/04/2018 05:11

** Ono Pharmaceutical  4528.T , maker of Opdivo, dives as
much as 11 pct to 2,506 yen, lowest since early December
    ** Merck & Co's  MRK.N  immunotherapy Keytruda plus
chemotherapy significantly improved overall survival in
newly-diagnosed patients with advanced non-small cell lung
cancer in a closely-watched study  urn:newsml:reuters.com:*:nL1N1RT0TZ
    ** Move cements its lead position over Bristol-Myers Squibb
Co and others in the most lucrative oncology market
    

 

 ((Reuters
Messaging:ayai.tomisawa.thomsonreuters.com@reuters.net)
)